logo
Share SHARE
FONT-SIZE Plus   Neg

Merck KGaA Says PETACC-8 Study Of Erbitux Shows No Benefit At Interim Analysis

Merck KGaA (MKGAY.PK) revealed results from an interim analysis of the Phase III clinical trial PETACC-81.

The study investigated the potential clinical utility of Erbitux (cetuximab) for the adjuvant treatment of stage III colon cancer after complete surgical removal of the primary tumor.

The pre-specified interim analysis of the study did not support benefit in disease free survival for patients given Erbitux plus standard chemotherapy (FOLFOX 4) compared with patients treated with FOLFOX 4 alone. Therefore this interim analysis does not support the use of Erbitux for the adjuvant treatment of stage III colon cancer in this setting.

"We are disappointed not to see an improvement in disease free survival after 3.3 years of median follow up" said Professor Julien Taïeb from the Hôpital Européen Georges Pompidou, Paris, and the PETACC-8 Principal Investigator. "Unfortunately, since the introduction of FOLFOX as standard treatment, all attempts to further improve prevention of disease recurrence have proved unsuccessful. We look forward to sharing our data at future scientific congresses."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stitch Fix, an online personal styling service, has filed for its initial public offering on Nasdaq, expecting to raise $100 million. The company, which was founded in 2011 by Katrina Lake, is reportedly seeking a valuation of up to $4 billion in the IPO. The proposed NASDAQ trading symbol is "SFIX". Play and entertainment company Hasbro, Inc. reported Monday higher profit in its third quarter, benefited by strong revenues in all regions. Both earnings and topline beat market estimates. The improvements were partly offset by negative impact of the Toys"R"Us bankruptcy in the U.S. and Canada. Looking ahead, the company projects higher revenues for the fourth quarter. Dutch consumer electronics giant Philips Electronics NV reported Monday lower attributable net income in its third quarter, while pre-tax income increased. Sales were flat on a reported basis, but grew 4 percent on a comparable basis mainly on growth in China. Further, the company said its outlook for 2017 remains unchanged despite ongoing global uncertainties.
comments powered by Disqus
Follow RTT